Efficacy of sunitinib rechallenge in kidney cancer: are mTOR inhibitors involved or is it only a matter of time?
Carlo Buonerba, Giuseppe Di Lorenzo
No abstract text available.
Antineoplastic Agents
Humans
Indoles
Kidney Neoplasms
Pyrroles
Sunitinib
TOR Serine-Threonine Kinases
Treatment Outcome
Antineoplastic Agents
Indoles
Pyrroles
MTOR protein, human
TOR Serine-Threonine Kinases
Sunitinib
